{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T22:10:55Z","timestamp":1793916655825,"version":"4.8.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"14","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T00:00:00Z","timestamp":1629417600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.jacc.2021.07.057","type":"journal-article","created":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T18:13:30Z","timestamp":1632766410000},"page":"1393-1403","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":174,"title":["Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial\u00a0Hypertension"],"prefix":"10.1016","volume":"78","author":[{"given":"Kelly M.","family":"Chin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Sitbon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Doelberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Simon R.","family":"Gibbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekkehard","family":"Gr\u00fcnig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius M.","family":"Hoeper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen C.","family":"Mathai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vallerie V.","family":"McLaughlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lo\u00efc","family":"Perchenet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Poch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajan","family":"Saggar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9rald","family":"Simonneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazzareno","family":"Gali\u00e8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"146","key":"10.1016\/j.jacc.2021.07.057_bib1","doi-asserted-by":"crossref","first-page":"170093","DOI":"10.1183\/16000617.0093-2017","article-title":"Pathobiology of pulmonary arterial hypertension: understanding the roads less travelled","volume":"26","author":"Hemnes","year":"2017","journal-title":"Eur Respir Rev"},{"issue":"1","key":"10.1016\/j.jacc.2021.07.057_bib2","doi-asserted-by":"crossref","first-page":"1801887","DOI":"10.1183\/13993003.01887-2018","article-title":"Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives","volume":"53","author":"Humbert","year":"2019","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.jacc.2021.07.057_bib3","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1183\/13993003.01032-2015","volume":"46","author":"Gali\u00e8","year":"2015","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.jacc.2021.07.057_bib4","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","volume":"37","author":"Gali\u00e8","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2021.07.057_bib5","doi-asserted-by":"crossref","first-page":"1801889","DOI":"10.1183\/13993003.01889-2018","article-title":"Risk stratification and medical therapy of pulmonary arterial hypertension","volume":"53","author":"Gali\u00e8","year":"2019","journal-title":"Eur Respir J"},{"issue":"9","key":"10.1016\/j.jacc.2021.07.057_bib6","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1056\/NEJMoa1413687","article-title":"Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension","volume":"373","author":"Gali\u00e8","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.jacc.2021.07.057_bib7","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s40256-017-0262-z","article-title":"Targeting the prostacyclin pathway with selexipag in patients with pulmonary arterial hypertension receiving double combination therapy: Insights from the randomized controlled GRIPHON study","volume":"18","author":"Coghlan","year":"2018","journal-title":"Am J Cardiovasc Drugs"},{"issue":"9","key":"10.1016\/j.jacc.2021.07.057_bib8","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1213917","article-title":"Macitentan and morbidity and mortality in pulmonary arterial hypertension","volume":"369","author":"Pulido","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.jacc.2021.07.057_bib9","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.chest.2019.09.009","article-title":"Risk reduction and right heart reverse remodeling by upfront triple combination therapy in pulmonary arterial hypertension","volume":"157","author":"D\u2019Alto","year":"2020","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.jacc.2021.07.057_bib10","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1183\/09031936.00116313","article-title":"Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study","volume":"43","author":"Sitbon","year":"2014","journal-title":"Eur Respir J"},{"issue":"26","key":"10.1016\/j.jacc.2021.07.057_bib11","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1056\/NEJMoa1503184","article-title":"Selexipag for the treatment of pulmonary arterial hypertension","volume":"373","author":"Sitbon","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.07.057_bib12","unstructured":"Clinical Trial Data Transparency. Accessed September 14, 2021. https:\/www.janssen.com\/clinical-trials\/transparency."},{"key":"10.1016\/j.jacc.2021.07.057_bib13","unstructured":"Yale Open Data Access [YODA] Project site. Accessed September 14, 2021. http:\/\/yoda.yale.edu."},{"key":"10.1016\/j.jacc.2021.07.057_bib14","doi-asserted-by":"crossref","first-page":"2000673","DOI":"10.1183\/13993003.00673-2020","article-title":"Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension","volume":"56","author":"Sitbon","year":"2020","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.jacc.2021.07.057_bib15","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1183\/09031936.00137511","article-title":"Selexipag, an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension","volume":"40","author":"Simonneau","year":"2012","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.jacc.2021.07.057_bib16","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.chest.2021.01.066","article-title":"Relationship between time from diagnosis and morbidity\/mortality in pulmonary arterial hypertension: results from the phase III GRIPHON study","volume":"160","author":"Gaine","year":"2021","journal-title":"Chest"},{"issue":"8","key":"10.1016\/j.jacc.2021.07.057_bib17","first-page":"334","article-title":"Beta blockers in heart failure haemodynamics, clinical effects and modes of action","volume":"9","author":"de Milliano","year":"2001","journal-title":"Neth Heart J"},{"issue":"9049","key":"10.1016\/j.jacc.2021.07.057_bib18","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(97)80008-6","article-title":"Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease","volume":"349","year":"1997","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.jacc.2021.07.057_bib19","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1161\/CIRCULATIONAHA.108.839274","article-title":"Tadalafil therapy for pulmonary arterial hypertension","volume":"119","author":"Gali\u00e8","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.07.057_bib20","first-page":"PA5458","article-title":"Macitentan in pulmonary hypertension (PH): data from OPUS and OrPHeUS real-world data sets","volume":"54","author":"Kim","year":"2019","journal-title":"Eur Respir J"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109721058460?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109721058460?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:44:35Z","timestamp":1760017475000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109721058460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":20,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S0735109721058460"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2021.07.057","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.740874439.793588845","asserted-by":"object"}]},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial\u00a0Hypertension","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2021.07.057","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}